Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M

Apyx Medical Corp

Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).
Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.
Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.
FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.
Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.